Why the study?
Does ticlopidine improve walking ability, hemodynamics, or prothrombotic abnormalities in men with atherosclerotic intermittent claudication?
Population
51 men with atherosclerotic intermittent claudication and haemorheological abnormalities
Design
RCT, randomised, double-blind
Follow-up
1 year
Authors
Loading...
No benefit on walking ability or hemodynamics in claudication despite platelet inhibition; challenges antiplatelet monotherapy for improving peripheral perfusion outcomes.
Does ticlopidine improve walking ability, hemodynamics, or prothrombotic abnormalities in men with atherosclerotic intermittent claudication?
Ticlopidine provides sustained platelet inhibition but does not improve clinical or hemodynamic outcomes in men with atherosclerotic intermittent claudication.
Aukland et al. (1982) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: